Page 2 - தேசிய ஆராய்ச்சி நெறிமுறைகள் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covid-19: Bangavax to get conditional approval for clinical trials, says BMRC

Covid-19: Bangavax to get conditional approval for clinical trials, says BMRC
thedailystar.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailystar.net Daily Mail and Mail on Sunday newspapers.

Ruhul aminNational research ethics committeeBangladesh medical research councilGlobe biotechProf dr ruhul aminருஹுல் அமின்தேசிய ஆராய்ச்சி நெறிமுறைகள் குழுபங்களாதேஷ் மருத்துவ ஆராய்ச்சி சபைபூகோளம் பயோடெக்

Bangavax first buzzed with hope, then fizzled

Obaidur Masum, Senior Correspondent, bdnews24.com Published: 06 May 2021 11:42 AM BdST Updated: 06 May 2021 11:51 AM BdST Globe Biotech, a Bangladeshi company, applied for permission to begin clinical trials of its COVID-19 vaccine candidate ‘Bangavax’ in January. But, over three months later, it has yet to receive the approval of the Bangladesh Medical Research Council. ); } As trials have yet to begin, it means the effectiveness of the domestically produced vaccine is still unknown. Globe Biotech applied for approval to begin testing on humans, known as a clinical trial, on Jan 17. According to the rules, applications are first screened by the BMRC’s National Research Ethics Committee. If the BMRC gives its ethical consent, it goes to the Directorate General of Drug Administration. There it will wait for the consideration and approval of the National Clinical Trial Advisory Committee.

Ruhul aminSyed modasser aliMohammad mohiuddinNational research ethics committeeGlobe pharmaceuticalsWorld health organizationDrug administrationClinical research organisation ltd on janNational clinical trial advisory committeeResearch ethicsDirectorate generalNational clinical trial advisoryClinical research organisation ltdGlobe biotechCorona virusGlobe biotech

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United kingdomSouth koreaLaurent heirendtDaniele proverbioNiels juchemMinistry of higher educationLuxembourg ministry of higher educationMinistry of healthLuxembourg national research fundEuropean research councilNational research ethics committee of luxembourg comitLuxembourg ministriesHigher educationView largeNational research ethics committeeEthique de recherche

Vietnam enters second phase of Covid-19 vaccine trials - VnExpress International

Vietnam enters second phase of Covid-19 vaccine trials By Chi Le, Anh Thu February 26, 2021 | 09:14 pm GMT+7 A man in Long An Province is injected with Nanocovax, a Vietnamese Covid-19 vaccine, as part of the second phase of its human trials, February 26, 2021. Photo by VnExpress/Quynh Tran. Vietnam began the second phase of domestic Covid-19 vaccine human trials Friday with 73 volunteers. Thirty-five volunteers in Hanoi and 38 in southern Long An Province were divided into four groups for the second phase of human trials of Nanocovax, a Vietnamese Covid-19 vaccine produced by Nanogen Pharmaceutical Biotechnology JSC. Groups would be injected with placebos, as well as 25 microgram, 50 microgram and 75 microgram doses each. Volunteers would not know which type of shot they received.

Han iRepublic ofNational research ethics committeeEthics committeeMinistry of healthPasteur instituteVietnam military medical universityLong an provinceNanogen pharmaceutical biotechnologyPrime minister vu duc damVietnam military medicalNational research ethicsஹான் நான்குடியரசு ஆஃப்தேசிய ஆராய்ச்சி நெறிமுறைகள் குழுநெறிமுறைகள் குழு

Challenges and opportunities associated with cervical cancer screening programs in a low income, high HIV prevalence context

Cervical cancer is a leading cause of death among Cameroon women. The burden of cervical cancer is in part traceable to the inadequate understanding of socio-contextual determinants of access to screening and prevention opportunities. We explored multilevel individual, community and structural factors that facilitate or inhibit cervical cancer prevention in women at risk in a low-income, high HIV prevalence context. We utilized an exploratory qualitative approach to obtain data through focus group discussions and in-depth interviews from May to August, 2018. A two-stage purposive sampling strategy was used to select 80 women and 20 men who participated in 8 focus group discussions and 8 in-depth interviews. The socio-ecological model guided data analyses to identify micro-, meso-, and macro-level determinants of cervical cancer screening. Micro-level factors including lack of awareness and knowledge about cervical cancer, lack of access to information, excessive cost of cervical cancer

New yorkUnited statesSud ouestAtlantic oceanNational research ethics committeeCentral africa international epidemiology database to evaluateResearch assistants rasInstitutional review boardsAlbert einstein collegeRegional hospitalLimbe regional hospitalResearch assistantsபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்சூட் ஓஊெஸ்ட்அட்லாண்டிக் கடல்